NETRF’s 2021 accomplishments were possible because of you! With the support of our donors, NET researchers, and the patient community, we had a successful year that surpassed our expectations. Thank you for your wonderful generosity.
BOSTON, Mass. – The Neuroendocrine Tumor Research Foundation (NETRF) today announced $4.1 million in neuroendocrine tumor (NET) research funding to support the development of new
The fourteenth annual NETRF Research Symposium successfully concluded last month with over 300 registered virtual attendees participating from around the globe for the second year in a row. The meeting included nearly 60 talks and posters representing the cutting edge of NET research where investigators reported their latest data and discoveries to share and discuss with colleagues. This year posters were available for viewing over the three days preceding the two-day meeting, resulting in over 300 poster views and ample time for discussions. Over 95% of registrants attended the two-days of talks and live discussions while the recorded talks and posters were viewed by over 100 more attendees over the following week.
Dr. Thirlwell, the Mireille Gillings Professor of Cancer Genomics at the University of Exeter Medical School will assume the role in January of 2022. She is internationally renowned for advancing NET research, the clinical management of NETs and the integrated genomic analysis of cancer.
The phase 1a/1b clinical trial is being conducted in patients who have advanced small cell lung cancer, poorly differentiated neuroendocrine cancer, or pancreatic cancer. Satya Das, MD, MSCI, at Vanderbilt University Medical Center serves as principal investigator of the study, which is sponsored by the National Cancer Institute.
The California family resumed an in-person event to raise money for NETRF in honor of wife and mother Julie Firsty.
Promising clinical trial using Lutetium 177 in LungNETS.